https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-oral-cavity-mouth-cancer-likelihood-of-approval/
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Oral Cavity (Mouth) Cancer.
ifinatamab deruxtecandaiichi sankyooral cavitymouth cancer
https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
ifinatamab deruxtecandaiichi sankyoheadnecksquamous
https://www.businesswire.com/news/home/20230907552809/en/Ifinatamab-Deruxtecan-Continues-to-Demonstrate-Durable-Responses-in-Patients-with-Advanced-Small-Cell-Lung-Cancer-in-Early-Trial
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
ifinatamab deruxtecancontinuesdemonstratedurableresponses
https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-melanoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-282812&utm_campaign=recommended-articles-pi
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Melanoma.
ifinatamab deruxtecandaiichi sankyomelanomalikelihoodapproval